Front Matter

Main Article Content

PARKINSON’S DISEASE: PATHOGENESIS AND CLINICAL ASPECTS
Thomas B. Stoker, BA (Hons) MB BChir MRCP (UK) (ed)
Julia C. Greenland, MBBS MRes MRCP (UK) (ed)

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

Section
Prelim
Author Biographies

Thomas B. Stoker, BA (Hons) MB BChir MRCP (UK) (ed), John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, UK

Tom_150.jpg Dr. Tom Stoker is a neurologist, currently based at Addenbrooke’s Hospital, Cambridge, United Kingdom. After completing an intercalated degree in biological and biomedical sciences, he completed his medical degree at the University of Cambridge in 2012. Since then he has worked at a number of hospitals across the east of England, and he is currently working as a clinical research associate at the John van Geest Centre for Brain Repair at the University of Cambridge. His research involves the use of cell reprogramming techniques to study the mechanisms of, and test putative disease-modifying treatments for, Parkinson’s disease, with a particular interest in GBA1 mutation-associated Parkinson’s disease.

Julia C. Greenland, MBBS MRes MRCP (UK) (ed), John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, UK

Julia_150.jpgDr. Julia Greenland is a neurologist at Addenbrooke’s Hospital, Cambridge, United Kingdom. She graduated from Newcastle University in 2011 with a medical degree and an intercalated MRes degree, with a research focus on Parkinson’s disease. Following this, she has worked in a number of hospitals in the north-east and south of England, including the National Hospital for Neurology and Neurosurgery in London. She is currently working as a clinical research associate at the John van Geest Centre for Brain Repair, University of Cambridge. She is researching the involvement of the immune system in Parkinson’s disease, with a focus on targeting the peripheral immune system as a disease-modifying strategy.